FDAnews
www.fdanews.com/articles/101809-bioalliance-pharma-acquires-european-rights-to-pafuramidine

BioAlliance Pharma Acquires European Rights to Pafuramidine

December 5, 2007

France’s BioAlliance Pharma has signed a licensing agreement with Immtech Pharmaceuticals covering the European commercialization rights to pafuramidine maleate.

Pafuramidine is in Phase III trials for the treatment of pneumocystis pneumonia in
AIDS patients and human African trypanosomiasis.

Immtech will receive an initial license fee of $3 million and up to an additional
$13 million if the drug is approved in Europe, BioAlliance said.

BioAlliance has negotiated an option to sell pafuramidine in Europe for malaria in travelers. Marketing approval for this indication will trigger additional payments to Immtech.